A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 354 participants.

Also called NCT07816198

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 354 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07816198
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07816198. Randomized; double masking; primary purpose treatment. Start 2026-09-30 (anticipated); primary completion 2028-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
AD-233A
Intervention (Drug)
AD-233B
Intervention (Drug)
AD-233C
Intervention (Drug)
AD-233D
Intervention (Drug)
AD-233A Placebo
Intervention (Drug)
AD-233B Placebo
Lead sponsor
Addpharma Inc. (class: industry)

Record details

Record id
cardio:ct-nct07816198
Content hash
25ba40165541f0009a554ca4c9b35fe0ce42a9626bbc54b4fd95a613545ccde2